Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

72.42 +3.04 (+4.38%)
Streaming Delayed Price Updated: 2:13 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
33 34 Next >
2 Soaring Stocks With More Upside Potential
Are these mid-cap stocks giants in the making? 
Via The Motley Fool
Is Now a Good Time to Buy CRISPR Therapeutics?
CRISPR shares have climbed more than 40% this year. 
Via The Motley Fool
3 Tech Stocks to Watch for Groundbreaking Innovations in 2030
If you’re a speculative investor here are three companies that are on the leading edge of what may be groundbreaking innovations by 2030. 
Via InvestorPlace
2 Monster Stocks to Buy Without Any Hesitation
These players each bring in billions of dollars in earnings every year. 
Via The Motley Fool
Cathie Wood Is Buying These 3 Growth Stocks Hand Over Fist. Should You?
The captain of innovation-focused investing can't seem to get enough of these beaten-down growth stocks. 
Via The Motley Fool
3 Pharma Stocks That AI is Loving in July
Artificial intelligence recommends that these are the three stocks to consider when investing in pharma stocks. 
Via InvestorPlace
2 Magnificient Growth Stocks to Buy in July
These two growth stocks might be incredibly undervalued right now. 
Via The Motley Fool
Vertex Pharmaceuticals Stock: Bear vs. Bull
Vertex has reached a key moment in its story. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
These companies are coming into their own. 
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy With $100 Right Now
These stocks may not stay this low for long. 
Via The Motley Fool
3 Top Biotech Stocks Defying the Bear Market
Each has the potential to dramatically outperform the market. 
Via The Motley Fool
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
3 Things About Vertex Pharmaceuticals That Smart Investors Know
Vertex shares have advanced about 20% so far this year. 
Via The Motley Fool
2 Top Healthcare Stocks Defying the Bear Market
These stocks are rising in the double digits -- and outperforming the S&P 500. 
Via The Motley Fool
Sitting on Cash? These 2 Stocks Are Great Buys
Coca-Cola and Vertex Pharmaceuticals are excellent choices to add to your portfolio for the long term. 
Via The Motley Fool
3 Growth Stocks With 55% to 71% Upside, According to Wall Street
Find out why investment bank analysts are so bullish on these stocks. 
Via The Motley Fool
2 Growth Stocks That Might Be Too Cheap to Ignore
The sky is the limit for these healthcare companies. 
Via The Motley Fool
Thoughts For Thursday: Back From The Holiday With Caution
Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China. 
Via Talk Markets
3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025
In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 
Via InvestorPlace
Cathie Wood Continues To Sell Tesla Shares Amid Q2 Deliveries-Induced Strength: Here's How Much Shares Ark Offloaded Monday
 
Via Benzinga
3 Stocks That Every 20-Year-Old Should Buy Today
When you’re just starting out in adult life, you have time on your side. Use it to your advantage with these stocks for young investors. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023
If you dig deep enough, you’ll find some undervalued biotech stocks with substantial catalysts straight ahead. 
Via InvestorPlace
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Reaching profitability could be harder than investors expect. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both companies have therapies that should help grow revenue and earnings for years. 
Via The Motley Fool
The Best Stocks to Invest $20,000 in Right Now
You can invest in these companies with $20,000 -- or even a lot less. 
Via The Motley Fool
Why Shares of Nkarta Are Slumping Tuesday
The pharmaceutical stock dropped after announcing so-so clinical trial results. 
Via The Motley Fool
Wall Street Estimates That CRISPR Therapeutics Stock Could Jump 49%. Here's Why That's Right.
With two huge catalysts drawing near, its stock could go even higher. 
Via The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
3 Monster Stocks in the Making to Buy Right Now
They're not monsters now -- but just give them some time. 
Via The Motley Fool
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.